Eli Lilly and Company (NYSE:LLY) Trading Down 1.3%

Eli Lilly and Company (NYSE:LLY)’s stock price dropped 1.3% during mid-day trading on Thursday . The stock traded as low as $718.30 and last traded at $722.73. Approximately 958,152 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 3,012,311 shares. The stock had previously closed at $732.20.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Morgan Stanley upped their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. Finally, JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Trading Up 1.2 %

The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market cap of $696.95 billion, a price-to-earnings ratio of 126.47, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34. The business has a 50 day moving average price of $761.79 and a 200-day moving average price of $666.06.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.09 earnings per share. As a group, research analysts expect that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of LLY. Warren Street Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 18.9% during the 3rd quarter. Warren Street Wealth Advisors LLC now owns 835 shares of the company’s stock worth $449,000 after buying an additional 133 shares during the last quarter. Olistico Wealth LLC lifted its holdings in Eli Lilly and Company by 2.7% during the 3rd quarter. Olistico Wealth LLC now owns 2,447 shares of the company’s stock worth $1,314,000 after buying an additional 65 shares during the last quarter. Gemmer Asset Management LLC lifted its holdings in shares of Eli Lilly and Company by 78.0% in the 3rd quarter. Gemmer Asset Management LLC now owns 1,340 shares of the company’s stock worth $720,000 after purchasing an additional 587 shares during the last quarter. Blue Fin Capital Inc. lifted its holdings in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Blue Fin Capital Inc. now owns 9,901 shares of the company’s stock worth $5,318,000 after purchasing an additional 86 shares during the last quarter. Finally, Aaron Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 12.9% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 6,012 shares of the company’s stock worth $3,229,000 after purchasing an additional 685 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.